Oviedo

• Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Ga … Ended
  2023-504834-23-00 11 2021-02-24 Advanced/Metastatic Gastroesophageal Adenocarcinoma
• Study to Investigate the Efficacy and Safety of CS1003 in Combination with Lenvatinib Compared to Placebo in Combination with Lenvatinib in … Ended
  2024-517331-48-00 5 2021-01-18 Unresectable advanced hepatocellular carcinoma
• A Study of Atezolizumab with or without Tiragolumab in Participants with Unresectable Esophageal Squamous Cell Carcinoma whose Cancers have … Ended
  2022-502052-30-00 5 2020-10-27 Unresectable Esophageal Squamous Cell Carcinoma
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thro … Ended
  2023-510107-22-00 5 2020-10-27 Hematopoietic stem cell transplant-associated thrombotic microangiopat
• Double-blind (neither the patient nor the doctor knows treatment allocation of the patient), randomized, placebo-controlled, prospective pha … Ended
  2023-509737-39-00 5 2020-08-19 Primary infection prophylaxis in patients with chronic lymphocytic leu
• A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung) Ended
  2023-505035-12-00 5 2020-06-12 RET fusion−positive, metastatic Non-Small Cell Lung Cancer
• Treatment with Acalabrutinib in patients with chronic lymphocytic leukemia Ended
  2023-507669-24-00 5 2019-11-05 Chronic lymphocytic leukemia
• Pembrolizumab or Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced Ended
  2023-506657-38-00 5 2019-10-02 Biliary Tract Carcinoma
• Pembrolizumab with Lenvatinib versus Docetaxel for Metastatic NSCLC after Platinum Doublet Chemotherapy and Immunotherapy Ended
  2022-501439-18-00 5 2019-06-26 NSCLC with squamous or nonsquamous histology
• Adjuvant Therapy with Pembrolizumab Versus Placebo in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Su … Ended
  2022-501971-24-00 5 2019-05-20 Adjuvant treatment of HCC
• Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in HER2 Positive Advanced Gastric or GEJ Adenocarcinoma Ended
  2023-508253-98-00 5 2018-10-05 Gastric or gastroesophageal junction (GEJ) adenocarcinoma
• A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negati … Ended
  2023-508472-11-00 5 2018-06-13 Patients with early breast cancer
• Clinical trial to compare the efficacy and tolerability of fulvestrant (FaslodexTM) 500mg with placebo versus fulvestrant (FaslodexTM) 500mg … Ended
  2024-516132-10-00 4 2016-02-05 Metastatic breast cancer
• A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC af … Ended
  2023-509137-39-00 5 2015-11-06 Stage IB (T ≥ 4 cm), II and IIIA NSCLC
• Normal saline versus lactated Ringer’s solution for acute pancreatitis resuscitation, an open-label multicenter randomized controlled trial: … Ended
  2023-509879-16-00 6 Acute pancreatitis
• Phase 3 Study of Tamibarotene Plus Azacitidine in Patients Selected for RARA-positive Higher-risk MDS (SELECT-MDS-1) Ended
  2023-510361-97-00 5 Newly Diagnosed RARA-positive Adult Patients with Higher-risk Myelodys
• Simvastatin in the Prevention of Recurrent Pancreatitis, a Triple Blind, Randomized Controlled Trial. Ended
  2024-513188-17-03 6 Recurrent pancreatitis
• Metoprolol in Acute Respiratory Distress Syndrome (MAIDEN) Ended
  2024-515813-17-00 5 Acute Respiratory Distress Syndrome (ARDS)

Showing 289–306 of 306 trials